Provided is a monoclonal antibodies combing and inhibiting activation of epidermal growth factor relevant members Erbb3/HER3. The antibodies can be used for treating the esophagus cancer.
Figure 1A-1B are graphs summarizing results from an experiment to measure the neutralization activity of negative control (murine IgG (Δ)) and anti-ErbB3 monoclonal antibodies 04D01 (▪), 12A07 (◯), 18H02 (▯), 22A02 (□) and 24C05 (Q) to inhibit NRG1-β1 binding to hErbB3 (Figure 1A) and to measure the enhanced binding of NRG1-β1 to rhErbB3 by the anti-ErbB3 mAb 09D03 (▴) and 11G01 (*) (Figure 1B).
Figure 2 is a graph summarizing results from an experiment to measure the neutralization activity of negative control (murine IgG) and anti-ErbB3 monoclonal antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 to inhibit NRG1-al binding to rhErbB3.
Figure 3 is a graph summarizing results from an experiment to measure the cell surface recognition of the anti-ErbB3 antibodies of the chimeric protein Her2/3d2 expressed at the surface of CHO cells.
Figure 4 is a graph summarizing results from an experiment to measure the anti-proliferation activity of negative control IgG (murine IgG (Δ)) and anti-ErbB3 monoclonal antibodies 04D01 (▪), 09D03 (▾), 11G01 (♦), 12A07 (◯), 18H02 (⋄), 22A02 (▯) and 24C05 (□) in BaF/3 cells expressing Her2 and ErbB3 in presence of NRG1-β1.
Figure 5 is a graph summarizing results from an experiment to measure the anti-proliferation activity of anti-ErbB3 monoclonal antibodies 04D01 (▪), 09D03 (▾), 11G01 (♦), 12A07 (▪), 18H02 (⋄), 22A02 (▯) and 24C05 (□) in MCF7 cells in the presence of NRG1-β1.
Figure 6 is a graph summarizing results from an experiment to measure the anti-proliferation activity of negative control (murine IgG) and anti-ErbB3 monoclonal antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 in SKBR-3 cells treated with 5 μg/ml of antibodies in the presence of serum.
Figure 7 is graph summarizing results from an experiment to measure the inhibitory activity of negative control IgG and anti-ErbB3 monoclonal antibodies 04D01, 09D03, 11G01, 12A07, 18H02, 22A02 and 24C05 on the phosphorylation of ErbB3 induced by NRG in SKBR-3 cells.
Figure 8 is a graph summarizing results from an experiment to measure the tumor inhibitory activity of the anti-ErbB3 antibodies 04D01 (Δ), 09D03 (*), 11G01 (□), 12A07 (▴), 18H02 (▯), 22A02 (▪), 24C05 (◯) and a human IgG control (- -▪- -) dosed at 20 mg/kg in a BxPC3 pancreatic tumor xenograft model in CB 17 SCID mice (vehicle control, PBS (♦)).
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-1729-sdAb | Recombinant Anti-human ERBB3 VHH Single Domain Antibody | WB, ICC, ChiP, FA, ELISA | Llama VHH |
TAB-070CT | Llama Anti-ERBB3 Recombinant Single Domain Antibody (TAB-070CT) | FC, Block | Llama VHH |
PABC-556 | Recombinant Llama Anti-ERBB3 Single Domain Antibody (PABC-556) | ELISA, SPR | Llama VHH |
There are currently no Customer reviews or questions for HPAB-M0306-YC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.